Decline in Hutchmed's revenue during the initial half of 2025
Hutchmed's Revenue Dips Amidst Competition and Transitional Challenges
Hutchmed, a prominent Chinese pharmaceutical company, has reported a 9% decrease in revenue for the first half of 2025, with the total earnings standing at $277.7 million yuan. This decline was primarily due to a 22% drop in sales in China’s Oncology/Immunology segment, according to the company's half-year results released last Thursday.
Despite a 25% increase in sales of its best-selling drug, FRUZAQLA®, the revenue decline was not fully compensated. FRUZAQLA generated $43 million in revenue for the first half of 2025, marking a 1% year-on-year increase.
The intensified competition in the China colorectal cancer (CRC) market, transitional effects from recent organizational changes, and anti-corruption activities are some of the factors contributing to the decline in the Oncology/Immunology segment.
The revenue decline was not offset by the success of Hutchmed's best-selling drug. The company's net income, however, saw a significant increase due to a $416 million one-time gain from the disposal of a joint venture stake, unrelated to core sales performance.
The revenue decline was also observed in Hutchmed's next three best-selling drugs, with sales dropping by 27% to 50% in the first half of 2025.
In a surprising turn of events, Hutchmed's New York-listed stock fell 16.3% in the two trading days after the announcement, closing at $15 last Friday. Despite the stock's 4.5% increase this year, the recent decline may indicate investor uncertainty about the company's future performance.
[1] China Daily
[2] Reuters
[3] Bloomberg
[4] MarketWatch
[5] CNBC
- The finance sector, specifically investors, might show increased interest in Hutchmed's progress, as the declining revenue in its Oncology/Immunology segment could potentially impact the medical-conditions related business, namely cancer treatment.
2.urthermore, the recent decline in Hutchmed's revenue, caused by various factors including increased competition, organizational changes, and anti-corruption activities, could have implications for the company's overall business strategy and financial outlook.
